Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTIGA vs KEPPRA XR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective neuronal potassium channel opener; activates Kv7 channels (KCNQ) to stabilize neuronal membranes and reduce excitability.
Levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal excitability.
Adjunctive therapy for partial-onset seizures in adults
Adjunctive therapy for partial-onset seizures in adults and children aged ≥4 years,Adjunctive therapy for myoclonic seizures in adults and adolescents aged ≥12 years with juvenile myoclonic epilepsy,Adjunctive therapy for primary generalized tonic-clonic seizures in adults and children aged ≥6 years with idiopathic generalized epilepsy
100 mg orally once daily for 1 week, then increase by 50-100 mg/day at weekly intervals to 300-400 mg/day in 2 divided doses; maximum 400 mg/day.
1500 mg orally once daily (2 tablets of 750 mg). Extended-release formulation is taken once daily; immediate-release is dosed twice daily.
Terminal elimination half-life is approximately 13-16 hours in healthy individuals, allowing twice-daily dosing. In patients with hepatic impairment, half-life may be prolonged (up to 30 hours).
7.1 ± 1.1 hours in adults; 10–11 hours in elderly; prolonged in renal impairment (up to 25 hours in severe renal failure).
Primarily glucuronidation by UGT1A9 and UGT2B7; minor CYP2E1 involvement.
Metabolized primarily by hydrolysis of the acetamide group via enzymatic hydrolysis (not CYP450 dependent); forms inactive metabolite (UCB L057); ~24% of dose undergoes oxidative metabolism.
Renal excretion accounts for approximately 25-30% of the administered dose as unchanged drug; the remainder is eliminated as metabolites via the biliary/fecal route (up to 70%) and further metabolized. Total recovery in urine and feces is >90%, with fecal excretion being the major route.
Renal: 66% as unchanged drug; 27% as inactive metabolite (uch L057); biliary/fecal: negligible (<1%).
Approximately 40% bound to albumin, mainly to albumin with minor binding to alpha-1-acid glycoprotein.
<10%; binding to albumin (not extensive).
Volume of distribution is approximately 0.7 L/kg, indicating distribution into total body water, and is consistent with low tissue binding.
0.5–0.7 L/kg; suggests distribution into total body water.
Oral bioavailability is approximately 90% (due to high absorption with minimal first-pass effect).
100% for oral tablet (immediate-release); 100% for extended-release (relative to immediate-release).
For Cr Cl 30-79 m L/min: 50 mg once daily for 1 week, then 100 mg twice daily; for Cr Cl 15-29 m L/min: 50 mg once daily for 1 week, then 50 mg twice daily; for Cr Cl <15 m L/min or hemodialysis: 50 mg once daily with post-dialysis supplementation of 50 mg.
For Cr Cl > 80 m L/min: 1500 mg once daily; Cr Cl 50-80 m L/min: 1000 mg once daily; Cr Cl 30-49 m L/min: 500 mg once daily; Cr Cl < 30 m L/min: 250 mg once daily. ESRD on dialysis: 500 mg once daily with 250 mg supplemental dose post-dialysis.
Child-Pugh A: no adjustment; Child-Pugh B: 50 mg once daily for 1 week, then 100 mg twice daily; Child-Pugh C: not recommended.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). For severe hepatic impairment (Child-Pugh C), reduce dose by 50%.
For children ≥4 years with partial-onset seizures: 1.5 mg/kg/day (maximum 50 mg/day) orally once daily for 1 week, then increase to 3 mg/kg/day (or 100 mg/day) in 2 divided doses for week 2, followed by 4.5 mg/kg/day (or 150 mg/day) in 2 divided doses for week 3, then maintenance of 6 mg/kg/day (or 200 mg/day) in 2 divided doses.
For children ≥12 years (≥40 kg): 1500 mg orally once daily. Not FDA-approved for <12 years; use immediate-release formulation for pediatric patients <12 years: starting dose 10 mg/kg twice daily, titrated to 30 mg/kg twice daily.
Start at 50 mg once daily for 1 week, then increase to 50 mg twice daily; consider lower doses due to age-related renal impairment; monitor renal function.
Elderly patients often have reduced creatinine clearance; dose should be adjusted based on renal function. Monitor for drowsiness, dizziness, and ataxia. Start at lower end of dosing range and titrate cautiously.
None.
No FDA black box warning.
Neuropsychiatric symptoms (hallucinations, confusion, psychosis),Increased risk of suicidal thoughts/behavior,QT prolongation (dose-dependent),Urinary retention,PR interval prolongation,Hepatotoxicity
Behavioral abnormalities including psychosis, aggression, hostility, irritability, and suicidal ideation/behavior,Somnolence and fatigue,Serious dermatologic reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis),Hematologic abnormalities (decreased red blood cell, white blood cell, and platelet counts),Increased blood pressure in pediatric patients,Withdrawal seizures upon abrupt discontinuation
Hypersensitivity to ezogabine or any component,Concurrent use with other potassium channel openers (e.g., retigabine),Severe hepatic impairment (Child-Pugh C)
Hypersensitivity to levetiracetam or any component of the formulation
No significant food interactions reported. Take with or without food. Avoid alcohol and grapefruit juice as they may exacerbate CNS effects or affect metabolism.
No significant food interactions. Grapefruit juice does not affect levetiracetam. Avoid alcohol as it may exacerbate CNS depression.
POTIGA (ezogabine) is classified as Pregnancy Category C. Limited human data; animal studies show fetal adverse effects at doses similar to human therapeutic doses. First trimester: potential for major malformations, but data insufficient. Second and third trimesters: risk of fetal toxicity and neonatal withdrawal. Should only be used if benefit outweighs risk.
Pregnancy Category C. First trimester: Increased risk of major congenital malformations (e.g., neural tube defects, cleft palate) with antiepileptic drug polytherapy; monotherapy association unclear but may be dose-dependent. Second/third trimester: Risk of fetal growth restriction, hemorrhagic disease of newborn (vitamin K deficiency due to enzyme induction). Perinatal: Neonatal withdrawal syndrome, sedation, and coagulopathy.
No data on excretion in human milk; M/P ratio unknown. Risk of infant sedation, poor feeding, and withdrawal. Caution advised; consider alternative therapies or discontinue breastfeeding.
Levetiracetam is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 1.0. Relative infant dose is low (2–7% of weight-adjusted maternal dose). Limited data suggest no adverse effects in breastfed infants, but monitor for drowsiness, poor feeding. Benefit likely outweighs risk in most cases.
Pregnancy can decrease ezogabine exposure due to increased clearance and volume of distribution; dose adjustments may be necessary to maintain efficacy. Monitor serum concentrations and clinical response, adjusting dose as needed. Postpartum, monitor for toxicity due to rapid clearance normalization and reduce dose accordingly.
Increased clearance of levetiracetam during pregnancy, particularly in the second and third trimesters (up to 50–60% higher). Dose adjustments may be required to maintain therapeutic trough levels (target 12–46 µg/m L). Consider therapeutic drug monitoring every 1–3 months and after delivery, with gradual dose reduction to pre-pregnancy levels within 1–2 weeks postpartum.
Potiga (ezogabine/retigabine) is a neuronal potassium channel opener indicated as adjunctive treatment for partial-onset seizures. Requires ophthalmic monitoring due to risk of retinal pigment changes (blue-gray discoloration) and potential visual field defects. Urothelial effects (urinary retention, dysuria) are common; assess baseline renal function. QT prolongation possible; avoid with other QT-prolonging drugs. Titrate slowly to minimize CNS effects (dizziness, somnolence, ataxia).
Keppra XR (levetiracetam extended-release) is dosed once daily due to its prolonged absorption profile. Therapeutic drug monitoring is not routinely required because of its predictable pharmacokinetics and wide therapeutic index. Adjust dose in renal impairment (Cr Cl < 80 m L/min) using ideal body weight; supplement dose after hemodialysis. May cause somnolence, dizziness, and behavioral changes (e.g., aggression, psychosis) especially in pediatric and elderly patients. Stevens-Johnson syndrome and angioedema are rare but serious adverse effects. Sudden discontinuation may precipitate withdrawal seizures; taper over at least 2 weeks.
Take exactly as prescribed; do not abruptly stop therapy.,May cause dizziness or drowsiness; avoid driving until effects known.,Report any vision changes, eye pain, or blue-gray discoloration of skin/nails/retina.,Report difficulty urinating or blood in urine immediately.,Avoid alcohol and other CNS depressants.,Use effective contraception if applicable (can reduce hormonal contraceptive efficacy).,Store at room temperature (68-77°F) in original container.,Do not double dose if missed; contact doctor for missed dose instructions.
Take exactly as prescribed once daily with or without food, at the same time each day.,Swallow tablet whole; do not crush, chew, or break.,Do not drive or operate heavy machinery until you know how this medicine affects you.,Contact your doctor immediately if you experience skin rash, blistering, swelling of face/lips, or difficulty breathing.,Inform your doctor of any history of depression, mood swings, aggressive behavior, or suicidal thoughts.,Report any worsening of seizures or new types of seizures.,If you are on dialysis, take the recommended supplement dose after each session.,Do not stop taking this medicine suddenly as it may cause withdrawal seizures.,Avoid alcohol while taking Keppra XR; it may increase drowsiness and dizziness.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTIGA vs KEPPRA XR, answered by our medical review team.
POTIGA is a Antiepileptic that works by Selective neuronal potassium channel opener; activates Kv7 channels (KCNQ) to stabilize neuronal membranes and reduce excitability.. KEPPRA XR is a Antiepileptic that works by Levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal excitability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTIGA and KEPPRA XR depend on the specific clinical indication. These are both Antiepileptic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTIGA is: 100 mg orally once daily for 1 week, then increase by 50-100 mg/day at weekly intervals to 300-400 mg/day in 2 divided doses; maximum 400 mg/day.. The standard adult dose of KEPPRA XR is: 1500 mg orally once daily (2 tablets of 750 mg). Extended-release formulation is taken once daily; immediate-release is dosed twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTIGA and KEPPRA XR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTIGA is classified as Category C. POTIGA (ezogabine) is classified as Pregnancy Category C. Limited human data; animal studies show fetal adverse effects at doses similar to human therapeutic doses. First trimester. KEPPRA XR is classified as Category C. Pregnancy Category C. First trimester: Increased risk of major congenital malformations (e.g., neural tube defects, cleft palate) with antiepileptic drug polytherapy; monotherapy a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.